MetaCap

Connect Biopharma Holdings Limited (CNTB)

NASDAQ: CNTBHealth CareBiotechnology: Pharmaceutical PreparationsUSD

0.59-0.0382 (-6.08%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

CNTB stock chart

Technical analysis

Key statistics

All statistics
Market cap
$38.05M
EPS (TTM)
-$1.14
52-week range
0.55 – 3.82
Day range
0.5897 – 0.6378
Volume / Avg
365.04K / 3.98M
Beta
—

52-week range

$0.55$3.82

CNTB stock today

Connect Biopharma (CNTB) closed at $0.59 on Nov 20, down 6.08% (-$0.0382), versus the S&P 500's 3.70% decline. Trading was light, with 365.04K shares changing hands, about 9% of the average daily volume. Shares are 84.6% below their 52-week high of $3.82, set on Mar 27, 2026 and 7.3% above the 52-week low of $0.55, near the bottom of the past year's range.

CNTB is down 79.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 80.6%. Connect Biopharma has posted a net loss over the last twelve months (EPS of -$1.14), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Connect Biopharma

Company profile

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Barry David Quart Pharm.D.
Headquarters
San Diego, CA
Employees
64
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, Connect Biopharma generated $64,000 in revenue, down 99.8% from fiscal 2024, the first decline in the 5 years shown. Connect Biopharma reported a net loss of $55.5 million, compared with a loss of $15.6 million a year earlier. Operating margin was -90740.6%.

Connect Biopharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$64.00K$26.03M$0——
Growth-99.75%————
Net income$-55.48M$-15.63M$-62.11M$-118.09M$-202.27M
EPS (diluted)$-1.00$-0.28$-1.13$-2.15$-3.88

Analyst forecast

Forecast

Consensus (8 analysts)

strong_buy

Avg. price target

$5.88+896.61%

  • Strong buy 1
  • Buy 7
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $9.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 16, 2026
EPS actual vs est.
$-0.26 vs $-0.27
Surprise
+3.70%

CNTB news

All CNTB news

Connect Biopharma peers

Health Care sector
CNTB peer companies
CompanyPrice% ChgMarket capCompare
SDEVStablecoin Development Corporation0.50-10.30%$36.90Mvs CNTB
PLRXPliant Therapeutics Inc.0.5951-4.02%$36.89Mvs CNTB
DWTXDogwood Therapeutics Inc.1.04-2.36%$39.57Mvs CNTB
GRCEGrace Therapeutics Inc.1.71-0.58%$35.97Mvs CNTB
TLPHTalphera Inc.0.7852+6.25%$40.80Mvs CNTB
ELTXElicio Therapeutics Inc.1.45-3.33%$41.05Mvs CNTB
CUECue Biopharma Inc.4.15-7.78%$34.69Mvs CNTB
MREOMereo BioPharma Group plc ADR0.26-5.45%$41.52Mvs CNTB

Indexes, lists and sector

Connect Biopharma stock FAQ

What is Connect Biopharma's stock price today?

CNTB last traded at $0.59 as of Nov 20, 4:00 PM EST, down 6.08% on the day. Prices are delayed at least 15 minutes.

Who is Connect Biopharma's CEO?

Dr. Barry David Quart Pharm.D. is the chief executive officer of Connect Biopharma Holdings Limited, which has about 64 employees.

What is the CNTB 52-week high?

The 52-week high for CNTB is $3.82 and the 52-week low is $0.55. The stock is currently 84.6% below its high.

Compare CNTB